Sandu Pharma Reappoints Internal & Cost Auditors for FY27

Sandu Pharmaceuticals Ltd re-appointed Internal Auditors and Cost Auditor for the financial year 2026-27 during its Board Meeting held on May 5, 2026. The board also approved the standalone audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of ₹1 per equity share (10% on paid-up share capital), subject to shareholder approval. M/s Shekhar Joshi & Co was appointed as the Cost Auditor, while M/S Akhil Pai & Co and M/S Uday & Uday Associates were appointed as Internal Auditors for Goa and Mumbai operations, respectively.